Ophiomics is a clinical-stage Medtech company focused on advancing cancer diagnostics through innovative technologies that integrate bioinformatics, artificial intelligence (AI), and genomics. Their primary goal is to develop diagnostic tools that facilitate early cancer detection and optimize treatment selection, ultimately improving patient outcomes. Ophiomics employs a unique approach to biomarker discovery, utilizing a robust bioinformatics data-mining pipeline to identify clinically relevant biomarkers from large volumes of omics data. Their proprietary platforms, such as NOLO-Express and HYSEN-Liquid, are designed to streamline the development of in vitro diagnostic (IVD) medical devices, enabling efficient analysis of gene expression and circulating tumor DNA (ctDNA) while minimizing logistical challenges and costs.

The company's flagship product, HepatoPredict, exemplifies their commitment to precision medicine by providing prognostic information that aids clinicians in making informed decisions regarding liver cancer treatment. Ophiomics also emphasizes the importance of collaboration with clinicians, academia, and industry partners to enhance their diagnostic solutions. Their technological innovations, including the Versatile Sample Transport Box (VST-Box) and SpecimensDB, further support the efficient management and transport of biological samples, ensuring that their diagnostic products are accessible and seamlessly integrated into routine clinical practice. Through these advancements, Ophiomics aims to revolutionize cancer diagnostics and significantly impact global health outcomes.

Portugal

Ophiomics is a Biotech company developing new diagnostic products and services integrating bioinformatics and genomics in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in liver cancer.

Ophiomics

Company Details